O’Hara et al. conducted a small phase I dose-escalating study investigating the maximum tolerated dose (MTD) and tolerability of a CXCR4 antagonist in combination with the anti-PD-L1 Ab durvalumab in treatment-refractory advanced cancers (n = 9) [93]. The gene discussed is CXCR4; the disease is cancer.